Finch Therapeutics Group Stock (NASDAQ:FNCH)
Previous Close
$11.41
52W Range
$0.80 - $14.26
50D Avg
$11.67
200D Avg
$5.66
Market Cap
$19.35M
Avg Vol (3M)
$4.00K
Beta
1.33
Div Yield
-
FNCH Company Profile
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
FNCH Performance
Peer Comparison
Ticker | Company |
---|---|
NTRB | Nutriband Inc. |
DBTX | Decibel Therapeutics, Inc. |
BWV | Onconetix, Inc. |
IKNA | Ikena Oncology, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
STOK | Stoke Therapeutics, Inc. |
KPRX | Kiora Pharmaceuticals, Inc. |
LGVN | Longeveron Inc. |
REVB | Revelation Biosciences, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
HILS | Tharimmune, Inc. |
VRAX | Virax Biolabs Group Limited |
CCCC | C4 Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
DSGN | Design Therapeutics, Inc. |
RNXT | RenovoRx, Inc. |
HOWL | Werewolf Therapeutics, Inc. |
XLO | Xilio Therapeutics, Inc. |
CELC | Celcuity Inc. |
ELYM | Eliem Therapeutics, Inc. |